Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

Purpose: To investigate maximum tolerated dose (MTD), activity and predictive biomarkers of olaparib with carboplatin in BRCA wild-type (BRCAwt) high grade serous ovarian carcinoma (HGSOC) patients. Methods: A 3+3 dose escalation study examined olaparib capsules (400 mg twice daily [BID], days 1–7)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Lampert, Erika J., Hays, John L., Kohn, Elise C., Annunziata, Christina M., Minasian, Lori, Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Chiou, Victoria L., Figg, William D., Houston, Nicole, Lee, Jung-Min
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499601/
https://ncbi.nlm.nih.gov/pubmed/31080557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados